Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4175408 · 1 trial · 5 indications
Per investigator assessed Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
| Arm | Type | Description |
|---|---|---|
| Phase 1a Dose Escalation (Cohort A1) | EXPERIMENTAL | Escalating doses of LY4175408 administered intravenously (IV) |
| Phase 1a Dose Optimization (Cohort A2) | EXPERIMENTAL | Two or more doses of LY4175408 (evaluated during dose escalation) administered IV |
| Phase 1b Dose Expansion (Cohort B1) | EXPERIMENTAL | LY4175408 administered IV followed by pembrolizumab administered IV |
| Phase 1b Dose Expansion (Cohort B2) | EXPERIMENTAL | LY4175408 administered IV followed by pembrolizumab administered IV and either carboplatin administered IV or cisplatin administered IV |
| Phase 1b Dose Expansion (Cohorts C1, C2 and C3) | EXPERIMENTAL | LY4175408 administered IV |
| Name | Type | Description |
|---|---|---|
| LY4175408 | DRUG | IV infusion |
| Pembrolizumab | DRUG | IV infusion |
| Carboplatin | DRUG | IV infusion |
| Cisplatin | DRUG | IV infusion |
Inclusion Criteria: * Have one of the following advanced or metastatic solid tumor cancers: * Non-small cell lung cancer (NSCLC) * Small cell lung cancer (SCLC) * Endometrial cancer * Triple negative breast cancer (TNBC) (characterized by HR-negative disease and HER2-negative expression ac...
LY4175408 is an investigational small molecule being developed for the treatment of advanced cancer, including non-small-cell lung carcinoma, small cell lung carcinoma, endometrial neoplasms, neoplasm metastasis, and triple negative breast cancer. It is currently in Phase 1 clinical development.
The molecular target of LY4175408 has not been disclosed. It is a small molecule being studied for its potential anti-cancer activity in advanced solid tumors, including non-small-cell lung carcinoma and other cancer types.
LY4175408 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY.
LY4175408 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study is currently recruiting participants with advanced cancer.
LY4175408 is being evaluated in a Phase 1 clinical trial with the identifier NCT07046923, titled "A Study of LY4175408 in Participants With Advanced Cancer." The trial is recruiting and aims to enroll 240 participants across multiple countries, including the United States, China, France, Japan, South Korea, and Spain.